Bristol-Myers Squibb Company today announced that Part 1 a of the Phase 3 CheckMate -227 trial evaluating Opdivo ® plus low-dose Yervoy ® met the co-primary endpoint of overall survival, demonstrating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback